3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
311
Carcinoma, Non-Small-Cell Lung
282
Prostatic Neoplasms
160
Colorectal Neoplasms
155
Carcinoma, Hepatocellular
144
Neoplasms
134
Leukemia, Myeloid, Acute
132
Lung Neoplasms
115
Squamous Cell Carcinoma of Head and Neck
108
Triple Negative Breast Neoplasms
102
Multiple Myeloma
102
Recurrence
99
Pancreatic Neoplasms
94
Stomach Neoplasms
93
Ovarian Neoplasms
87
Neoplasm Metastasis
87
Lymphoma, Large B-Cell, Diffuse
81
Sarcoma
70
Precursor Cell Lymphoblastic Leukemia-Lymphoma
68
Esophageal Neoplasms
67
Uterine Cervical Neoplasms
66
Melanoma
65
Brain Neoplasms
65
Rectal Neoplasms
62
Head and Neck Neoplasms
62
Glioblastoma
60
Carcinoma, Renal Cell
57
Lymphoma
55
Myelodysplastic Syndromes
54
Esophageal Squamous Cell Carcinoma
54
Interventions
pembrolizumab
1
Paclitaxel
1
Carboplatin
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Recruiting
×
Squamous Non-small Cell Lung Cancer
×
Clear all
NCT07221474
2026-05-28
INTerpath-13
Merck Sharp & Dohme LLC
Phase 2
Recruiting
180 enrolled